Simon Falk joins Immedica, a specialty pharma commercialization and distribution company with high performing capabilities in Europe and the Middle East.
Simon Falk has an impressive experience from previous CFO positions. Most recently serving as CFO for MRG Group where he was heavily involved in the listing on Nasdaq Stockholm in 2016. Prior to that he was the CFO for Kronans Apotek Sweden’s third largest pharmacy chain during the first 5 years of operation. He has also been the CFO of several companies in the Telenor and Tele2 Group.
“Immedica is pleased to have recruited Simon Falk as CFO”, says Anders Edvell, CEO. “Simon will be instrumental in facilitating Immedica’s continuous growth in Europe and Middle East, to the ultimate benefit of patients with rare diseases in these territories” concludes Anders Edvell.
About Immedica Pharma
Immedica is a fast-growing private niche pharma group. Its headquarter is based in Stockholm, Sweden, and it has commercial coverage across Europe and the Middle East.
Immedica provides significant know-how and experience from commercialization of niche/specialty care products across Europe and the Middle East, and the company’s management team has an outstanding track record of operating niche pharma products internationally. Immedica has capabilities to provide optimal access of specialty care medicines to patients with significant medical needs, including key areas such as regulatory affairs, pharmacovigilance, medical affairs, pricing & reimbursement, quality and product distribution.
Immedica’s main owner is Impilo AB, a private Nordic investment company established in 2017, with more than SEK 3.6 billion in committed capital from leading Nordic and international investors.
For more information
Anders Edvell, CEO, Immedica
+46 705 44 61 26